Padmavati Manchikanti

Dr. Padmavati Manchikanti


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
AAAnupam Apoorva
Anupam Apoorva
ARArun Prabhu Rameshbabu
Arun Prabhu Rameshbabu
SDSwagata Dasgupta
Swagata Dasgupta
SDSantanu Dhara
Santanu Dhara
PMPadmavati Manchikanti
Padmavati Manchikanti

27 August 2024 in Food Bioscience
Verified
Journal Article
Closed access
DBDebalina Bose
Debalina Bose
PMPadmavati Manchikanti
Padmavati Manchikanti


26 February 2024 in Asian Journal of Comparative Law
Verified
Journal Article
Open access
PDF file
SDSayantani Datta
Sayantani Datta
PMPadmavati Manchikanti
Padmavati Manchikanti
NBNiharika Sahoo Bhattacharya
Niharika Sahoo Bhattacharya
The significance of food is beyond its gastronomic value. Food symbolises a community's enriched past and holds cultural expressions and traditional knowledge. The linkage of food with religious beliefs, geo-climatic factors, social standards, and various health benefits builds the reputation of the food, which is essentially attributable to its geographic origin. Following the ratification of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), the contracting states that have enacted Geographical Indications (GI) legislation (particularly those in Asia) have come forward to protect foodstuffs as GI in order to safeguard their communities and their traditional knowledge associated with foodstuffs. Against this background, the present article attempts to compare foodstuff GIs in eight selected Asian countries with a sui generis system of GI protection as TRIPS compliance. The comparative analysis of the evolution and scope of foodstuff protection, pre-registration and post-registration impact, and quality maintenance provides important insights into convergence and divergence among the selected Asian countries. The study further identifies policy implications for the sustenance of GI.

14 June 2025 in Biodiversity and Conservation
Verified
Journal Article
Closed access
PDF file
KGKavya Gupta
Kavya Gupta
PMPadmavati Manchikanti
Padmavati Manchikanti

24 August 2023 in Medical Law Review
Verified
Journal Article
Open access
PDF file
NMNidhi Mehrotra
Nidhi Mehrotra
PMPadmavati Manchikanti
Padmavati Manchikanti
Through the New Drugs and Clinical Trials Rules, 2019 (2019 Rules), India has developed the rules governing post-trial access (PTA) to new drugs or investigational new drugs. However, inconsistencies and interpretational challenges exist in the application of the 2019 Rules and the Indian Council of Medical Research Guidelines 2017. This conflation poses a real harm to the trial participants, specifically the ones with limited access to healthcare facilities. Since drug laws in India do not expressly deal with other forms of access like the ‘Compassionate Use’ or ‘Expanded Access’ mechanism, demarcating the scope and describing the strategies for PTA are the need of the hour. We propose possible strategies to address inadequacies in the regulatory regime and establish ‘win–win’ situations among all stakeholders. We further argue that India is well positioned to provide leadership by developing detailed PTA provisions and may set a potential path for the other clinical trial host countries.